Sign in
Not yet recruitingPhase 1

Bispecific PSMAxCD3 Antibody CC-1 Applied Subcutaneously in Patients With Castration Resistant Prostate Carcinoma

Key facts

Who runs it
University Hospital Tuebingen
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
29 people, planned
Starts
1 Sept 2027
Expected to end
30 Jun 2031
Type of study
Interventional
Treatments tested
  • CC-1 and Toczilizumab
Record updated
16 November 2026

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (2)Hide the full registry criteria

Who can take part

  • Existence of a written informed consent; Patient aged ≥ 18, no upper age limit; Patient is able to understand and comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations; Metastatic CRPC after at least third line treatment; Disease progression confirmed by tumor marker or/and imaging; Serum testosterone levels <50 ng/dl (1.7 nM); At least one measurable lesion that can be accurately assessed at baseline by CT or MRI and is suitable for repeated assessment; Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2; Male patients with partners of child-bearing potential, who are sexually active, must agree to the use of two highly effective forms of contraception. This should be started from the signing of the informed consent and continue throughout period of taking study treatment and for 3 months after the last dose of study drug; PSMA-positivity of CRPC as determined by PSMA-PET; Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 14 days prior to study treatment:; Hemoglobin ≥ 9 g/dl (Transfusion of packed red blood cells prior to enrolment allowed); Neutrophil count ≥ 1,500/mm3; Platelet count ≥ 100,000/µl; Bilirubin ≤ 1.5 x upper limit of normal (ULN); ALT and AST ≤ 2.5 x ULN; PT-INR/PTT ≤ 1.5 x ULN; Creatine kinase ≤ 2.5 x ULN; Serum creatinine ≤1.5 mg/dl or creatinine clearance ≥ 60 ml/min

Who cannot take part

  • Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer; Concurrent or previous treatment within 30 days in another interventional clinical trial with an investigational anticancer therapy; Persistent toxicity (≥Grade 2 according to Common Terminology Criteria for Adverse Events [CTCAE] version 6.0) caused by previous cancer therapy, excluding alopecia and neurotoxicity (≤ 2 grade); Clinically significant xerostomia (dry mouth >1grade according to CTCAE V6.0); CNS manifestation of the tumor or tumor manifestation close to the CNS (e.g. spinal cord) as assessed by the investigator; Clinical signs of active infection (> grade 2 according to CTCAE version 6.0); History of HIV infection; Immunocompromised patients; Viral active or chronic hepatitis (HBV or HCV); History of autoimmune disease; History of relevant CNS pathology or current relevant CNS pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder); Epilepsy requiring pharmacologic treatment; Therapeutic anticoagulation therapy; Major surgery within 4 weeks of starting study treatment. Patients must have recovered from any effects of major surgery; Patients receiving any systemic chemotherapy or radiotherapy within 2 weeks prior to study treatment or a longer period depending on the defined characteristics of the agents used; Heart failure NYHA III/IV; Non-controlled hypertension, defined as mean blood pressure values of >130 mmHg or >90 mmHg for systolic or diastolic, respectively; Severe obstructive or restrictive ventilation disorder; Known history of GI-perforation; Known intolerance to CC-1, tocilizumab or other immunoglobulin drug products as well as hypersensitivity to any of the excipients present in the respective drug products (CC-1, tocilizumab)

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • Prostate cancer

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This trial is a phase I trial in patients with metastasized castration resistant prostate cancer (mCRPC) after failure of at least third-line therapy aiming to evaluate safety and efficacy of CC-1, a bispecific antibody (bsAb) with PSMAxCD3 specificity. CC-1 binds to human prostate-specific membrane antigen (PSMA) on prostate cancer cells as well as to tumor vessels of CRPC, thereby allowing for a dual mode of anti-cancer action. CC-1 was developed in a novel format which not only prolongs serum half-life but most importantly reduces off-target T cell activation with expected fewer side effects. Together with pre-emptive IL-6 receptor (IL-6R) blockade using tocilizumab, this allows for application of effective bsAb doses with expected high anticancer activity. The maximum tolerated dose (MTD) of once per week subcutaneously (SC) applied CC-1 has been established in the DKTK_PMO_1605 trial. This is a phase Ib trial to further explore the efficacy and safety of the MTD of SC CC-1.

Read full original descriptionShow less

A translational research program comprising, among others, analysis of CC-1 half-life and molecular profiling in liquid biopsies will serve to better define the mode of action of CC-1 and to identify biomarkers for further clinical development.

The group in the trial

  • CC-1 s.c.Treatment being tested

    The patients will receive CC-1 weekly as SC injection. In the first week of treatment step dosing (T1V1: (P1), T1V2: (P2), T1V3: target dose level (TDL)) are applied. For the first week of treatment patient will be treated as an inpatient until 48h after application of the first target dose at visit T1V3. Thereafter the TDL will be applied weekly. For the second application of the TDL of CC-1 (first application without step dosing) at T2V1 patient again will be treated as an inpatient until 24h after CC-1 application. If well tolerated and upon medical evaluation, the T3V1 and following doses may be administered in an out-patient setting

    Treatment: CC-1 and Toczilizumab

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase Ib to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific PSMAxCD3 Antibody CC-1 Applied Subcutaneously in Patients With Castration Resistant Prostate Carcinoma
Criteria questions
Built from NCT07940023, who can take part
Record updated
16 November 2026